Introduction:

Glioma is the most prevalent primary brain tumor, causing significant mortality and morbidity. lncRNAs have great potential in tumor-targeted therapy, including for glioma via sponging microRNAs. Previous studies have shown that LINC00900 and miR-186-5p likely play a significant role in glioma progression. However, the relationship between them has not been elucidated. The purpose of this study was to explore the role of LINC00900 in the prognosis of gliomas and its underlying molecular mechanisms.

Material and methods:

Matched tissue specimens were collected from 107 patients with gliomas. The level of LINC00900 was monitored by qRT-PCR, and a series of statistical analyses were performed to predict the correlation between LINC00900 and clinicopathologic features. Additionally, the dual-luciferase reporter assay was used to assess the interplay between LINC00900 and miR-186-5p. The regulatory effect of miR-186-5p on LINC00900 tumor promoter role was also estimated. Cell metastasis and proliferation of glioma cells were evaluated by Transwell assay and CCK8, respectively.

Results:

Upregulation of LINC00900 was noted in glioma tissues. A significant association was found for LINC00900 with WHO grade, tumor size, and Karnofsky performance status (KPS) of glioma patients. LINC00900 was found to be associated with poor patient prognosis. Additionally, LINC00900 negatively regulated the level of miR-186-5p and facilitated the proliferation and metastasis of glioma cells. The inhibitory effect caused by decreased LINC00900 in glioma could be reversed by a reduced level of miR-186-5p.

Conclusions:

LINC00900 in glioma was identified as an indicator of poor prognosis. In the mechanism, LINC00900 promoted glioma cell proliferation and metastasis by regulating miR-186-5p negatively.